Detalles de la búsqueda
1.
Estimated projection of incidence and mortality of alcohol-related liver disease in China from 2022 to 2040: a modeling study.
BMC Med
; 21(1): 277, 2023 07 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37501074
2.
Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.
Cancer Control
; 27(1): 1073274820902271, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107929
3.
First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
Cancer
; 125(20): 3526-3534, 2019 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31287562
4.
Activation of CD3 + TIM3 + T cells contributes to excessive inflammatory response during glucocorticoid treatment.
Biochem Pharmacol
; 212: 115551, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37044297
5.
Long-term glucocorticoid exposure persistently impairs CD4+ T cell biology by epigenetically modulating the mTORC1 pathway.
Biochem Pharmacol
; 211: 115503, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36924904
6.
First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
PLoS One
; 18(4): e0279786, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37053300
7.
Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis.
J Infect Public Health
; 16(6): 893-900, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37062164
8.
Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China.
Front Pharmacol
; 14: 1309930, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38259264
9.
Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States.
Clin Ther
; 45(10): 965-972, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37537015
10.
Glucocorticoid regulation of the mTORC1 pathway modulates CD4+ T cell responses during infection.
Clin Transl Immunology
; 12(8): e1464, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37649974
11.
Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma.
Front Pharmacol
; 13: 849189, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35559260
12.
Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis.
Front Pharmacol
; 13: 1003483, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36339555
13.
Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
Adv Ther
; 39(10): 4583-4593, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35943715
14.
Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China.
Front Pharmacol
; 13: 880280, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36091746
15.
Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer.
Front Pharmacol
; 13: 832215, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35517823
16.
Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review.
Front Pharmacol
; 13: 860109, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35496294
17.
Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer.
Front Pharmacol
; 13: 881787, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35712723
18.
Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Front Pharmacol
; 13: 778505, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35222020
19.
Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis.
Clin Rheumatol
; 41(1): 63-73, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34373933
20.
Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study.
Front Public Health
; 10: 955120, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36033760